Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration

Abstract

Submacular haemorrhages seem to be a significant adverse event following intravitreal bevacizumab in large occult choroidal neovascularisation and may affect visual outcomes. Prospective studies are required to establish the optimal dose of bevacizumab for larger lesion sizes or to identify the most appropriate anti-VEGF agent in large occult CNV with fibrovascular and serous PED lesions.

Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration

“…13,14 These complications, which seem to be more common with larger lesions and with specific characteristics, need to be considered as potential complications of treatment. 15 In this retrospective series, ranibizumab monotherapy was an effective treatment for sub-foveal haemorrhage secondary to CNV in ARMD. These results are comparable with those of studies in which therapy against vascular endothelial growth factor is combined with surgery to displace sub-foveal haemorrhage, suggesting that the displacement of sub-foveal haemorrhage may not be necessary.…”

Long-Term Follow-Up After Multiple Intravitreal Bevacizumab Injections for Exudative Age-Related Macular Degeneration

“…In 11 (23%) eyes, previous treatments had been performed including an intravitreal injection of triamcinolone acetonide, and an intravitreal injection of recombinant tissue plasminogen activator and pneumatic retinopexy to remove a fresh subfoveal hemorrhage, or photodynamic therapy. The mean number of intravitreal injections of bevacizumab was 8.6 ± 2.5 (range: [6][7][8][9][10][11][12][13][14].…”

“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21] Numerous studies showed a signifi cant increase in visual acuity shortly after the injections. Few long-term investigations with a follow-up ranging between 12 and 24 months, however, have been conducted so far.…”

Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review

“…In total, 13 prospective [24][25][26][27][28][29][30][31][32][33][34][35][36] and 12 retrospective [37][38][39][40][41][42][43][44][45][46][47]48 ] case series evaluating bevacizumab were analyzed ( Table 2). The number of included patients ranged between 12 and 625 (median: 48).…”

“…The remaining publications were conducted in one center. Funding sources were specified in 11 publications [26,[29][30][31][33][34][35]38,41,45,47]. A pharmaceutical sponsor, however, was not reported.…”